Clinical Trial Update: The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study [Phase 2, Phase 3]

View source ↗

Summary

The REMNANT study is a phase 2/3 clinical trial for multiple myeloma conducted at Oslo University Hospital, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Oslo University Hospital | Conditions: Multiple Myeloma | Phase 2, Phase 3 | Status: RECRUITING